Emcure Pharmaceuticals has scheduled its 45th Annual General Meeting (AGM) for Monday, September 21, 2026. The Board of Directors has recommended a final dividend of ₹3.60 per equity share of face value ₹10 each for FY26, representing a 36% payout rate.

The meeting will be held through video conferencing or other audio-visual means, in compliance with Ministry of Corporate Affairs and Securities and Exchange Board of India circulars. The event is set to begin at 11:00 am IST. Shareholders holding shares as of the cut-off date, Monday, September 14, 2026, are eligible to attend via the MUFG Intime India Private Limited platform.

Voting Timeline

Remote e-voting will commence on Friday, September 18, 2026, at 9:00 am IST and conclude on Sunday, September 20, 2026, at 5:00 pm IST. Members who have cast their votes via remote e-voting prior to the AGM will not be eligible to vote again during the meeting.

Dividend Details

Upon approval at the AGM, the dividend will be paid to members whose names appear in the Register of Members as at the close of business hours on Friday, September 4, 2026 (Record Date). For shares held in dematerialised form, the dividend will be paid based on beneficial ownership details furnished by the Depositories.

Members are advised to update their KYC details with Depositories and the Registrar and Transfer Agent to receive the final dividend directly through electronic credit. As per the Income Tax Act, dividend income is taxable in the hands of the recipient, and the company will deduct tax at source based on the member's residential status and submitted documents.

Annual Report Availability

The Notice of the 45th AGM and the Annual Report for FY26 are available on the company’s website and the registrar’s portal. The filing was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Newspaper advertisements were published in "Financial Express" and "Loksatta" on August 29, 2026.

Amruta Yangalwar, Company Secretary & Compliance Officer, signed the disclosure on August 29, 2026.

Emcure Pharmaceuticals submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year ending March 31, 2026, to the National Stock Exchange of India Limited and BSE Limited on August 28, 2026.

The disclosure was made pursuant to Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report forms an integral part of the company’s annual report for FY26 and is available on its corporate website.

Environmental Performance

The company reported a total energy consumption of 738,954.5369 GJ for FY26, an increase from 682,465.48405 GJ in the previous fiscal year. Renewable energy sources accounted for 477,828.8027 GJ of this total, while non-renewable sources contributed 261,125.7342 GJ. Energy intensity per rupee of turnover decreased to 14.09 from 15.57 in FY25.

Water consumption stood at 549,171.94 kilolitres, up from 510,736.01 kilolitres in FY25. Water intensity per rupee of turnover improved to 10.47 from 11.66. The company discharged only 140 kilolitres of water, compared to 10 kilolitres in the prior year, with all discharges sent to third parties without treatment.

Greenhouse gas emissions showed mixed trends. Scope 1 emissions rose to 30,082.433 tCO2e from 27,257.03 tCO2e. However, Scope 2 emissions declined to 46,458.97 tCO2e from 50,784.63 tCO2e. The combined emission intensity per rupee of turnover fell to 1.46 tCO2e/INR Mn from 1.78 tCO2e/INR Mn.

Waste Management

Total waste generated increased to 6,255.97 metric tonnes from 4,203.32 metric tonnes in FY25. Hazardous waste constituted the majority at 4,438.74 metric tonnes. The company recycled or recovered 3,459.81 metric tonnes of waste, a significant rise from 1,876.97 metric tonnes in the previous year. Waste disposed of via incineration and landfilling totaled 1,092.12 metric tonnes.

Employee Safety and Wellbeing

The workforce comprised 6,667 employees and 2,930 workers as of March 31, 2026. Female representation among permanent employees remained at 9%. The company reported three recordable work-related injuries: two involving employees and one involving workers. No fatalities were recorded. The Lost Time Injury Frequency Rate (LTIFR) was 0.805 for employees and 0.475 for workers.

Spending on employee wellbeing measures accounted for 0.13% of total revenue, down from 0.15% in FY25. All permanent employees and workers were covered by health and accident insurance.

Governance and Related Party Transactions

The report highlighted significant related party transaction exposure. Sales to related parties constituted 36% of total sales, up from 32% in FY25. Investments in related parties made up 98% of total investments. Purchases from related parties remained low at 3% of total purchases.

TÜV Rheinland India Pvt Ltd provided reasonable assurance for the BRSR core indicators and limited assurance for other disclosures. The assurance covered nine manufacturing sites and one corporate office across India.